Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biomerica (BMRA) Research & Development (2016 - 2026)

Biomerica's Research & Development history spans 17 years, with the latest figure at $178000.0 for Q1 2026.

  • On a quarterly basis, Research & Development fell 17.97% to $178000.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $835000.0, a 19.4% decrease, with the full-year FY2025 number at $1.0 million, down 31.39% from a year prior.
  • Research & Development hit $178000.0 in Q1 2026 for Biomerica, down from $193000.0 in the prior quarter.
  • Over the last five years, Research & Development for BMRA hit a ceiling of $495419.0 in Q2 2022 and a floor of $178000.0 in Q1 2026.
  • Historically, Research & Development has averaged $327318.8 across 5 years, with a median of $343000.0 in 2024.
  • Biggest five-year swings in Research & Development: soared 63.81% in 2022 and later plummeted 37.62% in 2024.
  • Tracing BMRA's Research & Development over 5 years: stood at $462000.0 in 2022, then fell by 10.82% to $412000.0 in 2023, then crashed by 37.62% to $257000.0 in 2024, then decreased by 24.9% to $193000.0 in 2025, then decreased by 7.77% to $178000.0 in 2026.
  • Business Quant data shows Research & Development for BMRA at $178000.0 in Q1 2026, $193000.0 in Q4 2025, and $212000.0 in Q3 2025.